A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas.
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Flucytosine (Primary) ; Stem cell therapies (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
- Focus Adverse reactions
- 06 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Jul 2012 Planned End Date changed from 1 Aug 2012 to 1 May 2014 as reported by ClinicalTrials.gov.
- 18 Aug 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.